Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
295M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
82.1M
-
Shares change
-
+2.21M
-
Total reported value, excl. options
-
$744M
-
Value change
-
+$18.2M
-
Put/Call ratio
-
0.88
-
Number of buys
-
79
-
Number of sells
-
-63
-
Price
-
$9.05
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q3 2019
228 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q3 2019.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.1M shares
of 295M outstanding shares and own 27.85% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (10.9M shares), BlackRock Inc. (9.6M shares), VANGUARD GROUP INC (8.34M shares), WASATCH ADVISORS INC (6.9M shares), STATE STREET CORP (5.02M shares), Bellevue Group AG (3.65M shares), CREDIT SUISSE AG/ (2.47M shares), FMR LLC (2.44M shares), CITADEL ADVISORS LLC (2.19M shares), and DIMENSIONAL FUND ADVISORS LP (2.12M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.